<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04259736</url>
  </required_header>
  <id_info>
    <org_study_id>KY2018-362</org_study_id>
    <nct_id>NCT04259736</nct_id>
  </id_info>
  <brief_title>Prospective Cohort Study of Molecular Mechanism of Lower Respiratory Tract Microbes in Patients With AECOPD</brief_title>
  <acronym>REASON</acronym>
  <official_title>A Prospective Cohort Study of Molecular Mechanism of Lower Respiratory Tract Microbes in Patients With Acute Obstructive Pulmonary Disease (AECOPD) by Regulating the Transcriptional Balance of NF-κB and PPARγ in Alveolar Macrophages</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Huashan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Huashan Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      How to reduce the rapid decline of lung function in patients with AECOPD is a clinically&#xD;
      urgent problem to be solved. Studies have suggested that there is a bacterial flora imbalance&#xD;
      in the lower respiratory tract of COPD patients. To explore the relationship between&#xD;
      microbiology and host immunity is a hot topic in the field of COPD. The investigators use NGS&#xD;
      (next generation sequencing) technology to fully explore the specific molecular mechanism of&#xD;
      the lower respiratory tract microbiome in patients with COPD by regulating the&#xD;
      transcriptional activities of NF-κB and PPARγ in alveolar macrophages, resulting in pulmonary&#xD;
      parenchymal remodeling and decreased lung function. In this study, a prospective cohort study&#xD;
      will be used to evaluate the effect of the lower respiratory tract microbiome on lung tissue&#xD;
      (alveolar space and pulmonary vascular) remodeling and pulmonary function decline in patients&#xD;
      with AECOPD.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be based on a prospective cohort design in patients with COPD who are&#xD;
      eligible for the study. Fifty patients who met the criteria for inclusion and exclusion of&#xD;
      COPD exacerbations and signed informed consent will participate in the study. The purpose of&#xD;
      this study is to evaluate the effect of the lower respiratory tract microbiome on lung tissue&#xD;
      remodeling, decreased lung function, and clinical symptoms in patients with AECOPD.&#xD;
&#xD;
      Baseline screening includes demographic data, medical history, combined medication records,&#xD;
      symptoms, signs, symptom scores, number of acute exacerbations, blood cells and inflammatory&#xD;
      factors, electrocardiogram, lung function, alveolar lavage fluid microbe NGS, and safety&#xD;
      observation indicators.&#xD;
&#xD;
      Patients will be followed up every 3 months for a period of 1 year. The primary and secondary&#xD;
      endpoints are as follows.&#xD;
&#xD;
      Primary endpoint： Changes in FEV1 (forced expiratory volume in the first second) within 1&#xD;
      year of follow-up&#xD;
&#xD;
      Secondary endpoint： Changes in CAT, CCQ, mMRC scores during 1 year of follow-up Changes in&#xD;
      lung function during 1 year of follow-up: FEV1 / FVC Changes in blood routine, IgE, and&#xD;
      eosinophil count within 1 year of follow-up Number of hospital admissions due to acute&#xD;
      exacerbation during 1 year of follow-up&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Year</target_duration>
  <primary_outcome>
    <measure>FEV1</measure>
    <time_frame>12 months</time_frame>
    <description>Forced expiratory volume in the first second</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CAT scores</measure>
    <time_frame>12 months</time_frame>
    <description>COPD Assessment Test score; Score: 0-10, Low impact; Score: 10-20, Moderate impact; Score 20-30, High impact; Score 30-40, Very high impact.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mMRC scores</measure>
    <time_frame>12 months</time_frame>
    <description>The modified British Medical ResearchCouncil (mMRC) questionnaire total score ranges from 0 to 4, with higher grades indicating more severe breathlessness.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>other lung function parameters</measure>
    <time_frame>12 months</time_frame>
    <description>FEV1/ FVC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of COPD exacerbation</measure>
    <time_frame>12 months</time_frame>
    <description>Number of Incidence of COPD exacerbation</description>
  </secondary_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Acute Exacerbation of Chronic Obstructive Pulmonary Disease</condition>
  <condition>Microbiome</condition>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Specimens include blood specimens and alveolar lavage fluid, used to detect blood routine,&#xD;
      peripheral blood inflammatory factors (IL-8, TNF-α, IL-17), alveolar tube lavage&#xD;
      microorganisms, and alveolar lavage fluid inflammatory factors (NF- κB, PPARγ, MMP-12,&#xD;
      TIMP-4).&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Fifty patients who met the criteria for inclusion and exclusion of COPD exacerbations and&#xD;
        signed informed consent will participate in the study. Patients will be followed up every 3&#xD;
        months for a period of 1 year.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with a diagnosis of acute exacerbation of chronic obstructive pulmonary&#xD;
             disease (AECOPD) according to the GOLD2018 guidelines (patients with FEV1pred&gt; 30% and&#xD;
             no concurrent respiratory failure);&#xD;
&#xD;
          2. Age ≥18, ≤80 years, regardless of gender;&#xD;
&#xD;
          3. No antibiotics have been used after this acute exacerbation;&#xD;
&#xD;
          4. Treatment according to GOLD guidelines;&#xD;
&#xD;
          5. Those with the following bronchoscopy indications:&#xD;
&#xD;
               1. Collect lower respiratory tract secretions for bacteriological examination;&#xD;
&#xD;
               2. Chest radiographs have invasive lesions of unknown origin;&#xD;
&#xD;
               3. bronchoalveolar lavage, bronchial administration and suction treatment;&#xD;
&#xD;
               4. unexplained hemoptysis or chronic irritating cough;&#xD;
&#xD;
               5. Bronchial obstructions such as localized wheezing, localized emphysema,&#xD;
                  obstructive pneumonia, or any atelectasis;&#xD;
&#xD;
               6. Suspected of trachea and bronchial tumors;&#xD;
&#xD;
               7. paralysis of the recurrent laryngeal or phrenic nerve of unknown cause;&#xD;
&#xD;
               8. Cancer cells or Mycobacterium tuberculosis are found in sputum and no lesions are&#xD;
                  found on chest radiograph;&#xD;
&#xD;
               9. Suspected of bronchial foreign bodies or stones;&#xD;
&#xD;
              10. diffuse lesions of the lungs or masses around the lungs that require lung biopsy,&#xD;
                  brushing, or lavage for cytology or bacteriological examination to confirm the&#xD;
                  diagnosis;&#xD;
&#xD;
              11. Patients who have a long-term indwelling cannula after tracheotomy and know&#xD;
                  whether the trachea is damaged or necrotic;&#xD;
&#xD;
              12. hilar swollen, unexplained lung mass;&#xD;
&#xD;
              13. Select lipiodol or iodine radiography of a lung lobe or segment.&#xD;
&#xD;
          6. Voluntary signed informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. active phase of tuberculosis;&#xD;
&#xD;
          2. Patients with malignant tumor disease;&#xD;
&#xD;
          3. patients with rheumatic diseases;&#xD;
&#xD;
          4. Patients with contraindications to bronchoscopy;&#xD;
&#xD;
          5. patients with mental illness;&#xD;
&#xD;
          6. Exclude those with severe medical diseases: such as heart, liver, and kidney&#xD;
             dysfunction or coagulation dysfunction; uncontrolled hypertension, hyperglycemia or&#xD;
             arrhythmia;&#xD;
&#xD;
          7. pregnancy and lactation;&#xD;
&#xD;
          8. Patients who participated in other clinical trials in the past 3 months;&#xD;
&#xD;
          9. Staff members and their families in this research institution.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shengqing Li, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Huashan Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shengqing Li, PhD</last_name>
    <phone>+8602152887072</phone>
    <email>shengqingli9655@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jingwen Xia, MD</last_name>
    <phone>+8602152887072</phone>
    <email>xjw2006@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Huashan hospital,Fudan university</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200040</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shengqing Li, PhD</last_name>
      <phone>02152887072</phone>
      <email>shengqingli9655@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Jingwen Xia, MD</last_name>
      <phone>+8602152887072</phone>
      <email>xjw2006@126.com</email>
    </contact_backup>
    <investigator>
      <last_name>Jingwen Xia, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 3, 2020</study_first_submitted>
  <study_first_submitted_qc>February 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 6, 2020</study_first_posted>
  <last_update_submitted>February 5, 2020</last_update_submitted>
  <last_update_submitted_qc>February 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Huashan Hospital</investigator_affiliation>
    <investigator_full_name>Shengqing Li</investigator_full_name>
    <investigator_title>Chief Physician,Professor</investigator_title>
  </responsible_party>
  <keyword>Lower Respiratory Tract</keyword>
  <keyword>Microbes</keyword>
  <keyword>COPD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

